Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28159773.
- Also identified by DOI 10.1136/thoraxjnl-2016-209397.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The impact of immunosuppression on interferon-γ release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-α responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-γ, IL-2 and TNF-α responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-α agents significantly impair interferon-γ release assay performance. IP-10 may be a more robust TB biomarker than interferon-γ in patients receiving corticosteroids.
Medical subject headings
- Adrenal Cortex Hormones
- Antirheumatic Agents
- Infliximab
- Interferon-gamma Release Tests
- Latent Tuberculosis